4SC AG gets EUR 41m after successful capital increase
We are excited to announce the participation in the EUR 41m capital increase of 4SC AG. a listed biopharmaceutical company from Germany. The company develops low-molecular-weight cancer treatment methods. On a related note, we congratulate 4SC on their licensing agreement with Maruho Co., Ltd. The agreement covers global exclusive rights for a pre-clinical substance class and entitles 4SC to up to EUR 103m in pre-payments and up to EUR 105m in commercial milestone payments, in addition to a sales commission.